Name | Number of supported studies | Average coverage | |
---|---|---|---|
retinal cone cell | 6 studies | 29% ± 11% | |
GABAergic neuron | 3 studies | 38% ± 9% | |
glutamatergic neuron | 3 studies | 46% ± 12% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 30% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 98% | 650.07 | 2599 / 2642 | 71% | 3.64 | 501 / 705 |
adrenal gland | 100% | 2354.98 | 258 / 258 | 37% | 6.66 | 86 / 230 |
ovary | 94% | 496.58 | 169 / 180 | 0% | 0.01 | 1 / 430 |
spleen | 77% | 116.62 | 185 / 241 | 0% | 0 | 0 / 0 |
kidney | 54% | 79.94 | 48 / 89 | 8% | 0.22 | 75 / 901 |
prostate | 56% | 102.43 | 138 / 245 | 4% | 0.06 | 19 / 502 |
eye | 0% | 0 | 0 / 0 | 55% | 5.29 | 44 / 80 |
blood vessel | 43% | 92.27 | 574 / 1335 | 0% | 0 | 0 / 0 |
heart | 32% | 46.76 | 274 / 861 | 0% | 0 | 0 / 0 |
thymus | 21% | 22.63 | 136 / 653 | 6% | 0.14 | 35 / 605 |
skin | 1% | 0.56 | 10 / 1809 | 14% | 0.94 | 66 / 472 |
lymph node | 0% | 0 | 0 / 0 | 10% | 0.17 | 3 / 29 |
uterus | 4% | 5.01 | 6 / 170 | 6% | 0.31 | 28 / 459 |
lung | 3% | 2.94 | 19 / 578 | 6% | 0.18 | 69 / 1155 |
peripheral blood | 8% | 7.62 | 78 / 929 | 0% | 0 | 0 / 0 |
bladder | 5% | 10.95 | 1 / 21 | 2% | 0.08 | 10 / 504 |
esophagus | 3% | 2.63 | 38 / 1445 | 3% | 0.28 | 6 / 183 |
intestine | 6% | 5.76 | 54 / 966 | 0% | 0.01 | 1 / 527 |
stomach | 4% | 3.57 | 13 / 359 | 1% | 0.01 | 2 / 286 |
pancreas | 0% | 0.21 | 1 / 328 | 2% | 0.08 | 4 / 178 |
breast | 0% | 0.33 | 2 / 459 | 2% | 0.05 | 22 / 1118 |
liver | 1% | 0.96 | 3 / 226 | 0% | 0.02 | 2 / 406 |
adipose | 1% | 0.93 | 13 / 1204 | 0% | 0 | 0 / 0 |
muscle | 0% | 0.44 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0051056 | Biological process | regulation of small GTPase mediated signal transduction |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0035556 | Biological process | intracellular signal transduction |
GO_0050771 | Biological process | negative regulation of axonogenesis |
GO_0016358 | Biological process | dendrite development |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0019898 | Cellular component | extrinsic component of membrane |
GO_0016020 | Cellular component | membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0005085 | Molecular function | guanyl-nucleotide exchange factor activity |
GO_0005515 | Molecular function | protein binding |
Gene name | MCF2 |
Protein name | MCF.2 cell line derived transforming sequence MCF2 Proto-oncogene DBL (Proto-oncogene MCF-2) [Cleaved into: MCF2-transforming protein; DBL-transforming protein] |
Synonyms | DBL |
Description | FUNCTION: Guanine nucleotide exchange factor (GEF) that modulates the Rho family of GTPases. Promotes the conversion of some member of the Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1 exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but significant activity toward RAC1 and CDC42. Isoform 4 exhibits significant activity toward RHOA and CDC42. The truncated DBL oncogene is active toward RHOA, RAC1 and CDC42. |
Accessions | ENST00000370573.8 [P10911-2] ENST00000414978.5 [P10911-3] ENST00000520602.6 ENST00000446225.5 ENST00000370576.9 [P10911-1] ENST00000519895.6 [P10911-5] Q5JYJ5 H0Y662 A0A2X0SZ10 ENST00000437564.5 ENST00000338585.6 [P10911-4] A0A2U3TZL4 P10911 ENST00000536274.5 [P10911-6] |